A traditional Chinese medicine compound preparation for improving the efficacy of anti-pd-1 monoclonal antibody immunotherapy for colorectal cancer

By combining traditional Chinese medicine compound preparations with PD-1 monoclonal antibodies, the body's anti-tumor immune response is activated, which solves the problem of limited response to immunotherapy in dMMR/MSI-H colorectal cancer patients and achieves significant tumor growth inhibition and survival extension.

CN118576664BActive Publication Date: 2026-06-23SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Filing Date
2024-04-22
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

In current colorectal cancer treatments, patients with DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) have limited response to PD-1 monoclonal antibody immunotherapy and are resistant to it, resulting in insignificant treatment effects and difficulty in effectively inhibiting tumor growth.

Method used

The traditional Chinese medicine compound preparation consists of Rehmannia glutinosa, Ligustrum lucidum, Cremastra appendiculata, Cistanche deserticola, Akebia quinata, and Duchesnea indica. It is extracted by decoction and ethanol precipitation and prepared into a powder preparation. When used in combination with PD-1 monoclonal antibody, it activates the body's anti-tumor immune response and inhibits the growth of colorectal cancer.

Benefits of technology

It significantly improved the therapeutic effect of PD-1 monoclonal antibodies, reduced exhausted T cells, enhanced the body's anti-tumor immune response, and prolonged patient survival. It also has a significant effect on inhibiting the growth of colorectal cancer and improving the effectiveness of immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118576664B_ABST
    Figure CN118576664B_ABST
Patent Text Reader

Abstract

The present application relates to the field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine compound preparation capable of improving the curative effect of PD-1 monoclonal antibody on colorectal cancer, which is composed of six traditional Chinese medicines, namely, Radix Rehmanniae Preparata, Ligustri Lucidi Fructus, Hylotrupes, Herba Cistanche, Lonicerae Japonicae Flos and Duchesnea Indica. The traditional Chinese medicine compound preparation can effectively reduce the number of exhausted T cells in the body, activate the anti-tumor immune response of the body, and has a significant inhibitory effect on the growth of colorectal cancer when used in combination with PD-1 monoclonal antibody. The traditional Chinese medicine compound preparation can also be used as an auxiliary drug for dMMR (DNA mismatch repair deficiency) / MSI-H (microsatellite high instability) colorectal cancer patients, thereby effectively solving the clinical problem that dMMR / MSI-H colorectal cancer patients have limited response to PD-1 and other immunotherapies, and the traditional Chinese medicine compound preparation has a wide application prospect when used in combination with PD-1 monoclonal antibody.
Need to check novelty before this filing date? Find Prior Art